US Transdermal Patch Market Sales Revenue Opportunity Report 2020

The last two decades have witnessed multiple innovations and commercialization of new medical agents and drug delivery mechanism. These innovations in drug delivery systems have not only enabled the successful implementation of many of these novel pharmaceuticals products such as transdermal patches, but have also permitted the development of new medical treatments with existing drugs. The need of more innovation in field of transdermal drug delivery system is still huge and will remain so in the upcoming years of the medicinal world.

Download Report:

https://www.kuickresearch.com/report-US-Transdermal-Patch-Market-Outlook-2020.php

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

US Transdermal Patch Market Outlook 2020" Table of Contents

1. Introduction to Transdermal Patch

2. Classification of Transdermal Patches
2.1 Single/ Multiple-Layer Drug-in-Adhesive
2.2 Reservoir Transdermal Patches
2.3 Matrix Based Transdermal Patches
2.4 Vapor Patch
2.5 Active and Passive Patch

3. Why There Exist Need for Transdermal Patches?

4. Mechanism of Transdermal Patch Drug Delivery
4.1 Properties of Transdermal Therapeutics
4.2 Components of Transdermal Patch
4.3 Mechanism of Motion Sickness, Nicotine & Female Contraceptive Transdermal Patch

5. Transdermal Patch v/s Traditional Drug Delivery Methods

6. US Transdermal Patch Market Overview
6.1 Current Market Scenario
6.2 US Transdermal Patch Clinical Pipeline Overview

7. Generic & Branded Transdermal Patches

8. Value Chain Analysis for Transdermal Patch Market
8.1 Research & Development
8.2 Manufacturing
8.3 Marketing & Distribution
8.4 Price to End User


9. US Transdermal Patch Contract Manufacturing Organization (CMO)

10. US Transdermal Patch Market Opportunity Assessment
10.1 Parkinson’s Disease
10.2 Alzheimer's Disease
10.3 Female Contraceptive
10.4 Nicotine Replacement Therapy
10.5 Insulin
10.6 Vaccine

11. US Transdermal Patch Market Dynamics
11.1 Favorable Market Parameters
11.2 Commercialization Challenges

12. US Transdermal Patch Market Future Prospects

13. US Transdermal Patch Clinical Pipeline by Company, Indication & Phase
13.1 Research
13.2 Preclinical
13.3 Phase-I
13.4 Phase-I/II
13.5 Phase-II
13.6 Phase-II/III
13.7 Phase-III
13.8 Preregistration
13.9 Registered

14. Marketed Transdermal Patch Clinical Insight by Company & Indication


15. Discontinued & No Development Reported in US Transdermal Patch Clinical Pipeline
15.1 No Development Reported
15.2 Discontinued
15.3 Marketed Withdrawal

16. Competitive Landscape
16.1 3M Pharmaceuticals
16.2 Acrux
16.3 Agile Therapeutics
16.4 Allergan
16.5 ANI Pharmaceuticals
16.6 Antares Pharma
16.7 Bayer HealthCare Pharmaceuticals
16.8 Corium International
16.9 Chase Pharmaceuticals
16.10 DURECT Corporation
16.11 Endo Pharmaceuticals
16.12 Fempharm
16.13 Hisamitsu Pharmaceutical
16.14 Immune Pharmaceuticals
16.15 Imprimis Pharmaceuticals
16.16 Ipsen Bioscience
16.17 Johnson & Johnson
16.18 LaSalle Laboratories
16.19 Lavipharm-increase
16.20 MINRAD International
16.21 NeurogesX
16.22 Noven Pharmaceuticals
16.23 NuPathe
16.24 Nuvo Research
16.25 Novartis
16.26 Pain Therapeutics
16.27 ProStrakan
16.28 Purdue Pharma
16.29 Sanofi
16.30 Scilex Pharmaceuticals
16.31 Senju Pharmaceutical
16.32 Somerset Pharmaceuticals
16.33 Teikoku Seiyaku
16.34 Therapeutic Discovery Corporation
16.35 Transdermal Delivery Solutions Corp
16.36 UCB
16.37 Xel Pharmaceuticals
16.38 Zosano Pharma

Figure 1-1: Steps Involved in Transdermal Permeation
Figure 1-2: Ideal Properties of Transdermal Patch

Figure 2-1: Types of Commercially Available Transdermal Patch

Figure 4-1: Properties of Transdermal Therapeutics
Figure 4-2: Components of Transdermal Patch
Figure 4-3: Types of Permeation Enhancers
Figure 4-4: Schematic Representation of Iontophoresis
Figure 4-5: Mechanism of Scopolamine Transdermal Patch
Figure 4-6: Mechanism of Nicotine Transdermal Patch
Figure 4-7: Mechanism of Female Contraceptive Transdermal Patch

Figure 5-1: Issues with Traditional Drug Delivery Methods
Figure 5-2: Advantages of Transdermal Patch
Figure 5-3: Consistent Drug Supply by Transdermal Patch

Figure 6-1: Advantages of Transdermal Patches
Figure 6-2: Disadvantages of Transdermal Patches
Figure 6-3: US - Major Reasons Behind Growth of Transdermal Patches
Figure 6-4: US - Estimated Prescription Drug Spending (USD Billion), 2015-2020
Figure 6-5: US- Transdermal Drug Delivery System Market (US$ Billion), 2015-2020
Figure 6-6: US - Estimated Prescription Transdermal Patch Market by Volume (%), 2015 & 2020
Figure 6-7: US - Estimated Market Size of Prescription vs. Over-The-Counter Transdermal Patches (US$ Billion), 2015
Figure 6-8: US - Estimated Market Size of Prescription vs. Over-The-Counter Transdermal Patches (US$ Billion), 2020
Figure 6-9: US Transdermal Patch Pipeline by Phase (%), 2016
Figure 6-10: US Transdermal Patch Pipeline by Phase (Numbers), 2016
Figure 6-11: US Transdermal Patch Pipeline by Phase (%), 2016
Figure 6-12: US Transdermal Patch Pipeline by Phase (Numbers), 2016

Figure 7-1: Requirement in Generic Transdermal Patches
Figure 7-2: Reservations for Generic Transdermal Patches
Figure 7-3: US - Estimated Cost Comparison of Branded vs. Generic Contraceptive Patch
Figure 7-4: US - Estimated Cost Comparison of Cigarettes, Generic & Branded Nicotine Patches

Figure 8-1: Basic Features of Transdermal Patch Value Chain
Figure 8-2: Steps Involved in Transdermal Patch Manufacturing

Figure 9-1: Stages of Transdermal Patch Development
Figure 9-2: Advantages of Using Contract Manufacturing Organization for Transdermal Drug Delivery System
Figure 9-3: Requirements from Contract Manufacturing Organization for Transdermal Drug Delivery System

Figure 10-1: Potential Market Segments of Transdermal Drug Delivery Systems
Figure 10-2: US - Susceptibility of Parkinson Disease among Males and Females
Figure 10-3: US - Estimated Increase in Parkinson’s Disease Incidences
Figure 10-4: US - Estimated Financial Impact of Parkinson’s Disease on Economy (US$ Billion)
Figure 10-5: US - Parkinson’s Disease Incidences, 2015-2020
Figure 10-6: US - Estimated Sales of Neupro Patch, 2104-2020
Figure 10-7: US - Estimated Worldwide Sales of Neupro, 2014 & 2015
Figure 10-8: US - Male & Female Suffering from Alzheimer’s Disease (Million), 2015
Figure 10-9: US - Shares of Male & Female Suffering from Alzheimer’s Disease (%), 2015
Figure 10-10: US - Percentage of Elderly People Suffering from Alzheimer’s Disease, 2015
Figure 10-11: US - Estimated Increase in Alzheimer’s Incidences, 2015, 2025 & 2050
Figure 10-12: US - Estimated Incidences of Alzheimer’s Disease, 2015-2020
Figure 10-13: US - Exelon Patch Sales for Alzheimer s Disease, 2013 & 2014
Figure 10-14: Requirements of Female Contraceptive Transdermal Drug Delivery Systems
Figure 10-15: Benefits of Female Contraceptive Transdermal Drug Delivery System
Figure 10-16: US - Expected Revenues Generated by Xulane Patch (US$ Million), 2015-2020
Figure 10-17: US - Decrease in Number of Smokers due to Nicotine Patch, 2005 & 2013
Figure 10-18: Factors Responsible for Increased Consumption of Nicotine Patches
Figure 10-19: Rank of US among Different Diabetes Prone Countries
Figure 10-20: US - Estimated Increase in Diabetes Incidences, 2015-2020
Figure 10-21: Benefits of Insulin Transdermal Patch
Figure 10-22: Drawback of Insulin Transdermal Patch
Figure 10-23: Benefits of Vaccine Transdermal Patch
Figure 10-24: Drawbacks of Vaccine Transdermal Patch
Figure 10-25: US - Estimated HIV Incidences, 2015-2020

Figure 11-1: Transdermal Patch Market Favorable Factors
Figure 11-2: Transdermal Patch Market Commercialization Challenges

Figure 16-1: Acrux Clinical Pipeline
Figure 16-2: Agile Therapeutics Clinical Pipeline
Figure 16-3: Antares Pharma Clinical Pipeline
Figure 16-4: Corium International Clinical Pipeline
Figure 16-5: Durect Corporation Clinical Pipeline
Figure 16-6: Endo Pharmaceuticals Clinical Pipeline
Figure 16-7: Immune Pharmaceuticals Clinical Pipeline
Figure 16-8: Novartis Clinical Pipeline
Figure 16-9: Senju Pharmaceuticals Clinical Pipeline
Figure 16-10: Xel Pharamaceuticals Clinical Pipeline
Figure 16-11: Zosano Pharma Clinical Pipeline


Table 4-1: Transdermal Patches for Various Disease Indications

Table 6-1: Features Required in Transdermal Patches
Table 6-2: US - Different Transdermal Drug Delivery Systems Available in Market

Table 7-1: Similarities & Difference Between Generic & Branded Transdermal Patches
Table 7-2: US - Some Generic Transdermal Patches Available in Market

Table 8-1: Breakdown of Transdermal Patch Value Chain Analysis

Table 10-1: US - Estimated Adoption Rates for Parkinson s Disease Transdermal Patches , 2015-2020
Table 10-2: Description of Neupro Patch for Parkinson’s Disease
Table 10-3: US - Estimated Adoption Rates for Transdermal Drug Delivery Systems for Alzheimer s Disease, 2015-2020
Table 10-4: Transdermal Patches for Alzheimer’s Disease
Table 10-5: Description of Ortho Evra Contraceptive Patch
Table 10-6: Difference Between Generic & Branded Transdermal Contraceptive Products
Table 10-7: US-Estimated Adoption Rates for Transdermal Drug Delivery Systems for Diabetes Mellitus, 2015-2020
Table 10-8: US-Estimated Adoption rates for Transdermal Drug Delivery Systems for HIV, 2015-2020

Table 16-1: Pain Therapeutics Clinical Pipeline

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.